Hyperleptinemia contributes to antipsychotic drug-associated obesity and metabolic disorders.

ABSTRACT: Despite their high degree of effectiveness in the management of psychiatric conditions, exposure to antipsychotic drugs, including olanzapine and risperidone, is frequently associated with substantial weight gain and the development of diabetes. Even before weight gain, a rapid rise in circulating leptin concentrations can be observed in most patients taking antipsychotic drugs. To date, the contribution of this hyperleptinemia to weight gain and metabolic deterioration has not been defined. Here, with an established mouse model that recapitulates antipsychotic drug-induced obesity and insulin resistance, we not only confirm that hyperleptinemia occurs before weight gain but also demonstrate that hyperleptinemia contributes directly to the development of obesity and associated metabolic di

SUBMITTER: Zhao S 

PROVIDER: S-EPMC11755893 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature